StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) has partnered with DiagnoseAtHome, a multichannel health technology company specializing in at-home health and laboratory testing solutions.
What Happened: Through the partnership, StageZero will make its multi-cancer blood test, Aristotle, available to DiagnoseAtHome's patients in Canada and the U.S.
Built on StageZero's proprietary mRNA gene expression technology platform, Aristotle is a next-generation test that simultaneously screens for multiple cancers from a single blood sample.
Why It's Important: DiagnoseAtHome offers accessible at-home health and lab testing solutions, allowing businesses, organizations, and healthcare providers to provide safe, accurate, and discreet lab testing to patients as an alternative to in-person laboratory visits.
Price Action: SZLS shares are trading higher by 22.22% at C$0.11 on TSX on the last check Wednesday.
Photo Via Company
